Juliana Lopes Rangel Fietto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Juliana Lopes Rangel Fietto has a total of 207 co-authors. Here are the top co-authors by number of shared publications:
- Gustavo Costa Bressan
Departamento de Bioquímica e Biologia Molecular, Universidade Federal de Viçosa, Av. P. H. Rolfs, s/n, Campus Universitário, CEP: 36570-000 Viçosa, MG, Brasil
16 shared publications Gustavo Costa Bressan
Univ Fed Vicosa, Dept Biochem & Mol Biol, Av P H Rolfs,S N,Campus Univ, BR-36570000 Vicosa, MG, Brazil
9 shared publications- Raphael de Souza Vasconcellos
Federal University of Viçosa (UFV)
8 shared publications - Abelardo Silva-Júnior
Laboratório de Pesquisas em Virologia e Imunologia ‐ LAPEVI, Instituto de Ciências Biológicas e da Saúde ‐ ICBS Universidade Federal de Alagoas Maceió Alagoas Brazil
7 shared publications Abelardo Silva-Júnior
Departamento de Veterinária, Universidade Federal de Viçosa, Av. P. H. Rolfs s/n, Viçosa, Minas Gerais CEP: 36570-900, Brazil
5 shared publications- Christiane Mariotini-Moura
Federal University of Viçosa Viçosa Brazil
5 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by Elsevier in Microbial Pathogenesis
- Vol. 218, 108670
Serological diagnosis of canine leptospirosis using a chimeric protein based on bacterial surface antigens
- 30 June 2026
- Published by Elsevier in Microbial Pathogenesis
- Vol. 218, 108670
Open AccessSerological diagnosis of canine leptospirosis using a chimeric protein based on bacterial surface antigens
- Open Access
- 27 March 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (13) , 20270-20284
Bisamidine Derivatives as Candidates for Tegumentary Leishmaniasis Therapy: Phenotypic Screening in Infection of Macrophages and Mechanistic Insights with Dual RNA-seq
Leishmania braziliensis is the primary causative agent of American tegumentary leishmaniasis (ATL), a critical parasitic tropical neglected disease. The chemotherapeutic arsenal has limited efficacy and significant toxic effects that lead to an urgent need to develop new medicines. Using the “drug repurposing” approach, histone-modifying enzyme inhibitors have been the subject of developing new drugs against neglected parasitic diseases. In this work, furamidine, a known diphenyl furan inhibitor of human Protein Arginine Methyltransferase (PRMT), along with a library of 31 developed analogues, was tested for leishmanicidal activity against L. braziliensis in the in vitro infection of macrophage assay. The most active and selective leishmanicidal analogue, BSF2 (EC50 of 0.64 μM (95% CI: 0.56–0.72), SI of 17.36), was further investigated by dual RNA-seq at 0.16 μM BSF2. The dual-transcriptome detected only 10 genes with significant differential expression (FDR ≤10%) in L. braziliensis related to ubiquitination, chromatin remodeling, and peroxisomal membrane transport pathways, following BSF2 treatment of infected macrophages. In addition, BSF2 had a significant effect (FDR ≤5%) on the expression of 577 genes in the infected macrophages, including the downregulation of TNF, IL-17, NF-κB, and Toll-like receptor pathways. This work opens new venues for developing new chemotherapy for leishmaniasis based on BSF2 or derivatives and highlights the dual transcriptome as a valuable phenotypic assay tool to investigate host–parasite interactions for antileishmanial drug discovery.
- 27 March 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (13) , 20270-20284
Open AccessBisamidine Derivatives as Candidates for Tegumentary Leishmaniasis Therapy: Phenotypic Screening in Infection of Macrophages and Mechanistic Insights with Dual RNA-seq
Leishmania braziliensis is the primary causative agent of American tegumentary leishmaniasis (ATL), a critical parasitic tropical neglected disease. The chemotherapeutic arsenal has limited efficacy and significant toxic effects that lead to an urgent need to develop new medicines. Using the “drug repurposing” approach, histone-modifying enzyme inhibitors have been the subject of developing new drugs against neglected parasitic diseases. In this work, furamidine, a known diphenyl furan inhibitor of human Protein Arginine Methyltransferase (PRMT), along with a library of 31 developed analogues, was tested for leishmanicidal activity against L. braziliensis in the in vitro infection of macrophage assay. The most active and selective leishmanicidal analogue, BSF2 (EC50 of 0.64 μM (95% CI: 0.56–0.72), SI of 17.36), was further investigated by dual RNA-seq at 0.16 μM BSF2. The dual-transcriptome detected only 10 genes with significant differential expression (FDR ≤10%) in L. braziliensis related to ubiquitination, chromatin remodeling, and peroxisomal membrane transport pathways, following BSF2 treatment of infected macrophages. In addition, BSF2 had a significant effect (FDR ≤5%) on the expression of 577 genes in the infected macrophages, including the downregulation of TNF, IL-17, NF-κB, and Toll-like receptor pathways. This work opens new venues for developing new chemotherapy for leishmaniasis based on BSF2 or derivatives and highlights the dual transcriptome as a valuable phenotypic assay tool to investigate host–parasite interactions for antileishmanial drug discovery.
- Open Access
- 22 September 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (38) , 43891-43902
Structural Modeling of NTPDase-Substrate Complexes Preserving Catalytic Experimental Features
Members of the ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase) family play a pivotal role in hydrolyzing nucleoside triphosphates and diphosphates, modulating purinergic and pyrimidinergic signaling pathways. The NTPDases have therapeutic potential; gaining structural insights into NTPDase-substrate complexes would be valuable for optimizing these enzymes for therapeutic applications. However, such insights remain limited, posing challenges for effective optimization. Molecular docking often fails to capture experimentally characterized substrate conformations, leading to biologically irrelevant models. To address this, we developed a computational strategy that preserves experimentally observed substrate features while leveraging the active site's conservation across NTPDases. Our method identifies a canonical linear-like substrate conformation encompassing the phosphate tail and nucleobase ring conserved across experimental NTPDase structures. This approach enabled the modeling of Homo sapiens (Hs) NTPDases (HsNTPDase1-8) complexed with ATP, ADP, GTP, GDP, UTP, and UDP, accurately positioning metal ion cofactor and catalytic water molecules. The resulting models offer a reliable framework for studying enzyme-substrate interactions, paving the way for rational enzyme engineering and therapeutic exploration.
- 22 September 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (38) , 43891-43902
Open AccessStructural Modeling of NTPDase-Substrate Complexes Preserving Catalytic Experimental Features
Members of the ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase) family play a pivotal role in hydrolyzing nucleoside triphosphates and diphosphates, modulating purinergic and pyrimidinergic signaling pathways. The NTPDases have therapeutic potential; gaining structural insights into NTPDase-substrate complexes would be valuable for optimizing these enzymes for therapeutic applications. However, such insights remain limited, posing challenges for effective optimization. Molecular docking often fails to capture experimentally characterized substrate conformations, leading to biologically irrelevant models. To address this, we developed a computational strategy that preserves experimentally observed substrate features while leveraging the active site's conservation across NTPDases. Our method identifies a canonical linear-like substrate conformation encompassing the phosphate tail and nucleobase ring conserved across experimental NTPDase structures. This approach enabled the modeling of Homo sapiens (Hs) NTPDases (HsNTPDase1-8) complexed with ATP, ADP, GTP, GDP, UTP, and UDP, accurately positioning metal ion cofactor and catalytic water molecules. The resulting models offer a reliable framework for studying enzyme-substrate interactions, paving the way for rational enzyme engineering and therapeutic exploration.
- Open Access
- 27 May 2025
- Published by Open Exploration Publishing in Exploration of Neuroscience
- Vol. 4, 100691
ENTPDase inhibitors: therapeutic potential in infectious, inflammatory, and neuroinflammatory diseases
Ectonucleoside triphosphate diphosphohydrolases (ENTPDases), members of the cluster of differentiation 39 (CD39) family, are key regulators of purinergic signaling through the hydrolysis of tri and diphosphate nucleotides. These enzymes are expressed on the cell surface, extracellular environment, or within intracellular organelles such as the Golgi apparatus. ENTPDases play critical roles in modulating immune responses, inflammation, and neuroinflammation by controlling extracellular nucleotide availability in mammals. Moreover, they contribute to adenosine-mediated signaling in cooperation with 5’-nucleotidases (CD73). Pathogenic microorganisms also express ENTPDases, manipulating host purinergic signaling, suppressing adenosine triphosphate (ATP)-driven inflammation, and promoting immune evasion via increased adenosine production. Pathogenic parasites also express ENTPDases, manipulating host purinergic signaling, suppressing ATP-driven inflammation, and promoting immune evasion via increased adenosine production. Given their involvement in infection and inflammatory diseases, ENTPDases have emerged as promising pharmacological targets. This review comprehensively analyzes the ENTPDases from mammals and pathogenic parasites, emphasizing their role in purinergic signaling and their potential as therapeutic targets. While ENTPDase inhibitors hold promise for modulating inflammation and infection, their clinical translation faces challenges, including selectivity, off-target effects, and systemic alterations in purinergic homeostasis. Addressing these concerns through targeted drug delivery, allosteric modulation, and improved inhibitor specificity is crucial for therapeutic advancements.
- 27 May 2025
- Published by Open Exploration Publishing in Exploration of Neuroscience
- Vol. 4, 100691
Open AccessENTPDase inhibitors: therapeutic potential in infectious, inflammatory, and neuroinflammatory diseases
Ectonucleoside triphosphate diphosphohydrolases (ENTPDases), members of the cluster of differentiation 39 (CD39) family, are key regulators of purinergic signaling through the hydrolysis of tri and diphosphate nucleotides. These enzymes are expressed on the cell surface, extracellular environment, or within intracellular organelles such as the Golgi apparatus. ENTPDases play critical roles in modulating immune responses, inflammation, and neuroinflammation by controlling extracellular nucleotide availability in mammals. Moreover, they contribute to adenosine-mediated signaling in cooperation with 5’-nucleotidases (CD73). Pathogenic microorganisms also express ENTPDases, manipulating host purinergic signaling, suppressing adenosine triphosphate (ATP)-driven inflammation, and promoting immune evasion via increased adenosine production. Pathogenic parasites also express ENTPDases, manipulating host purinergic signaling, suppressing ATP-driven inflammation, and promoting immune evasion via increased adenosine production. Given their involvement in infection and inflammatory diseases, ENTPDases have emerged as promising pharmacological targets. This review comprehensively analyzes the ENTPDases from mammals and pathogenic parasites, emphasizing their role in purinergic signaling and their potential as therapeutic targets. While ENTPDase inhibitors hold promise for modulating inflammation and infection, their clinical translation faces challenges, including selectivity, off-target effects, and systemic alterations in purinergic homeostasis. Addressing these concerns through targeted drug delivery, allosteric modulation, and improved inhibitor specificity is crucial for therapeutic advancements.
- Open Access
- 6 May 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (19) , 19466-19479
Histone Deacetylase Inhibitors Show a Potential Leishmanicidal Effect against Leishmania braziliensis in a Mouse Infection Model and Lead to Less Toxicity than Glucantime
Leishmania braziliensis is the primary cause of cutaneous leishmaniasis (CL) in the New World. Current treatments have significant limitations, including severe side effects and parasite resistance. Histone deacetylases (HDAC) are critical regulators of chromatin structure and represent potential drug targets for leishmaniasis. This study evaluated three HDAC inhibitors (HDACi), TH60, TH74, and TH85, in BALB/c mice infected with L. braziliensis, comparing their efficacy to the standard treatment, glucantime. Two doses were tested, and lesion size, parasite load, kidney and liver enzyme levels, and histopathological analyses were carried out. HDACi effectively reduced lesion size and parasite presence, with lower toxicity and fewer organ alterations than glucantime. Among the tested compounds, TH60 was the best-tested HDACi. These findings highlight the potential application of the tested HDACi as leishmanicidal agents against L. braziliensis, positioning them as promising candidates for developing new drugs targeting cutaneous leishmaniasis.
- 6 May 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (19) , 19466-19479
Open AccessHistone Deacetylase Inhibitors Show a Potential Leishmanicidal Effect against Leishmania braziliensis in a Mouse Infection Model and Lead to Less Toxicity than Glucantime
Leishmania braziliensis is the primary cause of cutaneous leishmaniasis (CL) in the New World. Current treatments have significant limitations, including severe side effects and parasite resistance. Histone deacetylases (HDAC) are critical regulators of chromatin structure and represent potential drug targets for leishmaniasis. This study evaluated three HDAC inhibitors (HDACi), TH60, TH74, and TH85, in BALB/c mice infected with L. braziliensis, comparing their efficacy to the standard treatment, glucantime. Two doses were tested, and lesion size, parasite load, kidney and liver enzyme levels, and histopathological analyses were carried out. HDACi effectively reduced lesion size and parasite presence, with lower toxicity and fewer organ alterations than glucantime. Among the tested compounds, TH60 was the best-tested HDACi. These findings highlight the potential application of the tested HDACi as leishmanicidal agents against L. braziliensis, positioning them as promising candidates for developing new drugs targeting cutaneous leishmaniasis.
- Open Access
- 23 April 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (17) , 17565-17575
Synthesis and Antileishmanial Evaluation of N-Phenyl-2-phenoxyacetamides Derived from Carvacrol
Leishmaniasis, caused by protozoa of the genus Leishmania and transmitted by sandflies, remains prevalent in underdeveloped countries. The disease manifests in three clinical forms: cutaneous, mucocutaneous, and visceral, the latter being fatal without adequate treatment. Current therapies, including pentavalent antimonials, have important limitations, such as high toxicity and reduced efficacy. This study investigates synthetic compounds derived from carvacrol as potential therapeutic alternatives. Carvacrol serves as a precursor for the synthesis of carvacroxyacetic acid, a key intermediate in producing N-phenyl-2-phenoxyacetamides. Ten novel molecules were synthesized with yields ranging from 11% to 60%. All synthesized compounds were characterized using mass spectrometry, 1H NMR and 13C NMR. Additionally, the structure of compound 9 (C18H20FNO2) was confirmed by X-ray crystallography. Cytotoxicity assays with macrophages and Vero cells revealed that all ten N-phenyl-2-phenoxyacetamides exhibited low or no toxicity at the tested concentrations. Compounds 5 and 7 demonstrated significant antileishmanial activity against Leishmania braziliensis, outperforming both the untreated control and the precursor carvacroxyacetic acid (CA). Furthermore, their efficacy against the parasite exceeded for the activity of pure carvacrol reported in the literature. These findings highlight the significant potential of these compounds and emphasize the importance of further studies to elucidate their mechanisms of action and explore broader therapeutic applications.
- 23 April 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (17) , 17565-17575
Open AccessSynthesis and Antileishmanial Evaluation of N-Phenyl-2-phenoxyacetamides Derived from Carvacrol
Leishmaniasis, caused by protozoa of the genus Leishmania and transmitted by sandflies, remains prevalent in underdeveloped countries. The disease manifests in three clinical forms: cutaneous, mucocutaneous, and visceral, the latter being fatal without adequate treatment. Current therapies, including pentavalent antimonials, have important limitations, such as high toxicity and reduced efficacy. This study investigates synthetic compounds derived from carvacrol as potential therapeutic alternatives. Carvacrol serves as a precursor for the synthesis of carvacroxyacetic acid, a key intermediate in producing N-phenyl-2-phenoxyacetamides. Ten novel molecules were synthesized with yields ranging from 11% to 60%. All synthesized compounds were characterized using mass spectrometry, 1H NMR and 13C NMR. Additionally, the structure of compound 9 (C18H20FNO2) was confirmed by X-ray crystallography. Cytotoxicity assays with macrophages and Vero cells revealed that all ten N-phenyl-2-phenoxyacetamides exhibited low or no toxicity at the tested concentrations. Compounds 5 and 7 demonstrated significant antileishmanial activity against Leishmania braziliensis, outperforming both the untreated control and the precursor carvacroxyacetic acid (CA). Furthermore, their efficacy against the parasite exceeded for the activity of pure carvacrol reported in the literature. These findings highlight the significant potential of these compounds and emphasize the importance of further studies to elucidate their mechanisms of action and explore broader therapeutic applications.
- 29 August 2024
- Published by Elsevier in Veterinary Parasitology
- Vol. 331, 110299
Development and preliminary study of the rLiNTPDase2 rapid test: A lateral flow immunochromatographic assay for Canine Visceral Leishmaniasis
- 29 August 2024
- Published by Elsevier in Veterinary Parasitology
- Vol. 331, 110299
Development and preliminary study of the rLiNTPDase2 rapid test: A lateral flow immunochromatographic assay for Canine Visceral Leishmaniasis
- 24 November 2023
- Published by Springer Nature in Purinergic Signalling
- Vol. 20 (5) , 509-520
Heterologous expression and biochemical characterization of the recombinant nucleoside triphosphate diphosphohydrolase 2 (LbNTPDase2) from Leishmania (Viannia) braziliensis
Leishmania braziliensis is a pathogenic protozoan parasite that causes American Tegumentary Leishmaniasis (ATL), an important tropical neglected disease. ENTPDases are nucleotidases that hydrolyze intracellular and/or extracellular nucleotides. ENTPDases are known as regulators of purinergic signalling induced by extracellular nucleotides. Leishmania species have two isoforms of ENTPDase, and, particularly, ENTPDase2 seems to be involved in infectivity and virulence. In this study, we conducted the heterologous expression and biochemical characterization of the recombinant ENTPDase2 of L. braziliensis (rLbNTPDase2). Our results show that this enzyme is a canonical ENTPDase with apyrase activity, capable of hydrolysing triphosphate and diphosphate nucleotides, and it is dependent on divalent cations (calcium or magnesium). Substrate specificity was characterized as UDP>GDP>ADP>GTP>ATP=UTP. The enzyme showed optimal activity at a neutral to basic pH and was partially inhibited by suramin and DIDS. Furthermore, the low apparent Km for ADP suggests that the enzyme may play a role in adenosine-mediated signalling. The biochemical characterization of this enzyme can open new avenues for using LbNTPDase2 as a drug target. Graphical abstract
- 24 November 2023
- Published by Springer Nature in Purinergic Signalling
- Vol. 20 (5) , 509-520
Heterologous expression and biochemical characterization of the recombinant nucleoside triphosphate diphosphohydrolase 2 (LbNTPDase2) from Leishmania (Viannia) braziliensis
Leishmania braziliensis is a pathogenic protozoan parasite that causes American Tegumentary Leishmaniasis (ATL), an important tropical neglected disease. ENTPDases are nucleotidases that hydrolyze intracellular and/or extracellular nucleotides. ENTPDases are known as regulators of purinergic signalling induced by extracellular nucleotides. Leishmania species have two isoforms of ENTPDase, and, particularly, ENTPDase2 seems to be involved in infectivity and virulence. In this study, we conducted the heterologous expression and biochemical characterization of the recombinant ENTPDase2 of L. braziliensis (rLbNTPDase2). Our results show that this enzyme is a canonical ENTPDase with apyrase activity, capable of hydrolysing triphosphate and diphosphate nucleotides, and it is dependent on divalent cations (calcium or magnesium). Substrate specificity was characterized as UDP>GDP>ADP>GTP>ATP=UTP. The enzyme showed optimal activity at a neutral to basic pH and was partially inhibited by suramin and DIDS. Furthermore, the low apparent Km for ADP suggests that the enzyme may play a role in adenosine-mediated signalling. The biochemical characterization of this enzyme can open new avenues for using LbNTPDase2 as a drug target. Graphical abstract
- 17 November 2023
- Published by Springer Nature in Purinergic Signalling
- Vol. 20 (4) , 399-419
Synthesis of new non-natural l-glycosidic flavonoid derivatives and their evaluation as inhibitors of Trypanosoma cruzi ecto-nucleoside triphosphate diphosphohydrolase 1 (TcNTPDase1)
Trypanosoma cruzi is the pathogen of Chagas disease, a neglected tropical disease that affects more than 6 million people worldwide. There are no vaccines to prevent infection, and the therapeutic arsenal is very minimal and toxic. The unique E-NTPDase of T. cruzi (TcNTPDase1) plays essential roles in adhesion and infection and is a virulence factor. Quercetin is a flavonoid with antimicrobial, antiviral, and antitumor activities. Its potential as a partial inhibitor of NTPDases has also been demonstrated. In this work, we synthesized the non-natural l-glycoside derivatives of quercetin and evaluated them as inhibitors of recombinant TcNTPDase1 (rTcNTPDase1). These compounds, and quercetin and miquelianin, a natural quercetin derivative, were also tested. Compound 16 showed the most significant inhibitory effect (94%). Quercetin, miquelianin, and compound 14 showed inhibition close to 50%. We thoroughly investigated the inhibitory effect of 16. Our data suggested a competitive inhibition with a Ki of 8.39 μM (± 0.90). To better understand the interaction of compound 16 and rTcNTPDase1, we performed molecular dynamics simulations of the enzyme and docking analyses with the compounds. Our predictions show that compound 16 binds to the enzyme’s catalytic site and interacts with important residues for NTPDase activity. As an inhibitor of a critical T. cruzi enzyme, (16) could be helpful as a starting point in the developing of a future treatment for Chagas disease. Furthermore, the discovery of (16) as an inhibitor of TcNTPDase1 may open new avenues in the study and development of new inhibitors of E-NTPDases.
- 17 November 2023
- Published by Springer Nature in Purinergic Signalling
- Vol. 20 (4) , 399-419
Synthesis of new non-natural l-glycosidic flavonoid derivatives and their evaluation as inhibitors of Trypanosoma cruzi ecto-nucleoside triphosphate diphosphohydrolase 1 (TcNTPDase1)
Trypanosoma cruzi is the pathogen of Chagas disease, a neglected tropical disease that affects more than 6 million people worldwide. There are no vaccines to prevent infection, and the therapeutic arsenal is very minimal and toxic. The unique E-NTPDase of T. cruzi (TcNTPDase1) plays essential roles in adhesion and infection and is a virulence factor. Quercetin is a flavonoid with antimicrobial, antiviral, and antitumor activities. Its potential as a partial inhibitor of NTPDases has also been demonstrated. In this work, we synthesized the non-natural l-glycoside derivatives of quercetin and evaluated them as inhibitors of recombinant TcNTPDase1 (rTcNTPDase1). These compounds, and quercetin and miquelianin, a natural quercetin derivative, were also tested. Compound 16 showed the most significant inhibitory effect (94%). Quercetin, miquelianin, and compound 14 showed inhibition close to 50%. We thoroughly investigated the inhibitory effect of 16. Our data suggested a competitive inhibition with a Ki of 8.39 μM (± 0.90). To better understand the interaction of compound 16 and rTcNTPDase1, we performed molecular dynamics simulations of the enzyme and docking analyses with the compounds. Our predictions show that compound 16 binds to the enzyme’s catalytic site and interacts with important residues for NTPDase activity. As an inhibitor of a critical T. cruzi enzyme, (16) could be helpful as a starting point in the developing of a future treatment for Chagas disease. Furthermore, the discovery of (16) as an inhibitor of TcNTPDase1 may open new avenues in the study and development of new inhibitors of E-NTPDases.
- 27 October 2022
- Published by Elsevier in Acta Tropica
- Vol. 237, 106732
Leishmania infantum NTPDase1 and NTPDase2 play an important role in infection and nitric oxide production in macrophages
- 27 October 2022
- Published by Elsevier in Acta Tropica
- Vol. 237, 106732
Leishmania infantum NTPDase1 and NTPDase2 play an important role in infection and nitric oxide production in macrophages